レミケード・バイオシミラーの世界市場レポート 2025年

レミケード・バイオシミラー市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR22.4%で110億7,000万米ドルに成長します。予測期間の成長は、特許切れ、費用対効果の高い治療法に対する需要の高まり、バイオシミラー・パイプライン開発、償還政策、市場統合などに起因すると考えられます。予測期間の主な動向には、医師の処方行動、バイオシミラーライフサイクル管理、バイオシミラーの命名規則、バイオシミラーの互換性、バイオシミラーの実世界エビデンスなどがあります。

自己免疫疾患の罹患率の増加が今後のレミケード・バイオシミラー市場の成長を牽引すると予測されます。自己免疫疾患は、免疫系が誤って身体の組織や臓器を攻撃し、損傷を与える疾患です。レミケード・バイオシミラーは、症状を管理し炎症を抑える効果的な治療オプションを提供することで、自己免疫疾患の治療に活用されています。例えば、2023年7月、スコットランドの国家機関であるPublic Health Scotlandのデータによると、2022年に新たに多発性硬化症（MS）と診断された患者数は、2020年の85.7%から87.2%に増加し、491人の新規症例が報告され、2022年の総症例数は6,359人となった。このように、自己免疫疾患の罹患率の増加がレミケード・バイオシミラー市場の成長を促進しています。

ヘルスケア支出の増加は、今後数年間のレミケード・バイオシミラー市場の成長に大きな影響を与えています。ヘルスケア支出とは、特定の期間内にヘルスケア商品およびサービスに費やされる総額のことで、通常は年間ベースです。レミケードなどの生物学的製剤は高額になることが多いです。ヘルスケア支出の増加に伴い、コスト抑制と資源の効率的配分に注目が集まっています。バイオシミラー医薬品は、レミケードなどのオリジネーターである生物学的製剤に代わる、より経済的な代替品を提供します。例えば、2024年10月、米国の連邦政府機関であるメディケア・メディケイド・サービスセンターは、2022年の処方薬支出が8.4％増の4,059億米ドルに達し、2021年に記録された6.8％増を上回ったと報告しました。したがって、医療費の増加はレミケード・バイオシミラー市場を牽引すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界レミケード・バイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のレミケード・バイオシミラー市場：成長率分析
• 世界のレミケード・バイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のレミケード・バイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界レミケード・バイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のレミケード・バイオシミラー市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 100mg/10ml
• 500mg/50ml
• 世界のレミケード・バイオシミラー市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 潰瘍性大腸炎
• 関節リウマチ
• 強直性脊椎炎
• クローン病
• 乾癬性関節炎
• 尋常性乾癬
• 世界のレミケード・バイオシミラー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液疾患
• 腫瘍疾患
• 世界のレミケード・バイオシミラー市場、100 mg/10 mlのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用バイアル
• プレフィルドシリンジ
• 世界のレミケード・バイオシミラー市場、500 mg/50 mlのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用バイアル
• プレフィルドシリンジ

第7章 地域別・国別分析

• 世界のレミケード・バイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のレミケード・バイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レミケード・バイオシミラー市場：競合情勢
• レミケード・バイオシミラー市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck And Co. Inc.
• LG Chem Ltd.
• Nippon Kayaku Co. Ltd.
• Celltrion Inc.
• Nichi-iko Pharmaceutical Co. Ltd.
• Biocon Limited
• Alvotech S.A.
• MabPharm Ltd.
• Genor Biopharma Co. Ltd
• Shanghai Biomabs Pharmaceuticals Co. Ltd.
• Samsung Bioepis Co. Ltd.
• Biocad Biopharmaceutical Co
• EPIRUS Biopharmaceuticals Inc.
• Ranbaxy Laboratories Limited
• BioXpress Therapeutics SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• レミケード・バイオシミラー市場2029：新たな機会を提供する国
• レミケード・バイオシミラー市場2029：新たな機会を提供するセグメント
• レミケード・バイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A Remicade biosimilar is a biological drug that is similar to Remicade, and it is utilized in the treatment of certain autoimmune diseases in both adults and children. This type of medication is specifically designed to address autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

The main types of biosimilars in the Remicade biosimilars category come in strengths of 100 mg/10 ml and 500 mg/50 ml. The 100 mg/10 ml strength indicates the amount of drug in the dosage form or a unit of the dosage form, equivalent to 100 mg per 10 ml. The applications for these biosimilars include the treatment of conditions such as ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis, and plaque psoriasis. Additionally, they are used for various applications in the treatment of blood disorders and oncology diseases.

The remicade biosimilars market research report is one of a series of new reports from The Business Research Company that provides remicade biosimilars market statistics, including remicade biosimilars industry global market size, regional shares, competitors with a remicade biosimilars market share, detailed remicade biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the remicade biosimilars industry. This remicade biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.95 billion in 2024 to $4.93 billion in 2025 at a compound annual growth rate (CAGR) of 24.9%. The growth in the historic period can be attributed to the introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, and healthcare cost pressures

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $11.07 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.

The increasing incidence of autoimmune diseases is anticipated to drive the growth of the remicade biosimilar market in the future. Autoimmune diseases are conditions where the immune system erroneously attacks and damages the body's tissues and organs. Remicade biosimilars are utilized in treating autoimmune diseases by offering an effective therapeutic option to manage symptoms and reduce inflammation. For example, in July 2023, data from Public Health Scotland, a national organization in Scotland, indicated that in 2022, the number of newly diagnosed patients with multiple sclerosis (MS) rose to 87.2%, up from 85.7% in 2020, with 491 new cases reported, resulting in a total of 6,359 cases in 2022. Thus, the increasing incidence of autoimmune diseases is propelling the growth of the remicade biosimilar market.

The growing healthcare expenditure is significantly impacting the growth of the remicade biosimilar market in the coming years. Healthcare expenditure refers to the total amount spent on healthcare goods and services within a specific timeframe, typically on an annual basis. Biologic drugs, such as Remicade, are often costly. As healthcare spending increases, there is a heightened focus on cost containment and the more efficient allocation of resources. Biosimilars provide a more economical alternative to their originator biologics, including Remicade. For instance, in October 2024, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that prescription drug spending grew by 8.4%, reaching $405.9 billion in 2022, surpassing the 6.8% growth recorded in 2021. Therefore, the rising healthcare expenditure is expected to drive the remicade biosimilar market.

Innovation in product development is a notable trend in the Remicade biosimilar market, with major companies focusing on introducing innovative products to maintain their market position. An example is Amgen Inc., a US-based biotechnology company, which launched Amjevita in January 2023. Amjevita is a biosimilar version of AbbVie's Humira, designed to be as safe and effective as the original drug. With a lower cost than Humira, Amjevita offers patients a more affordable treatment option for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Major companies in the remicade biosimilar market are concentrating on creating innovative solutions, such as subcutaneous formulations, to achieve a competitive edge. Subcutaneous formulations of Remicade offer an alternative method of administration for treating autoimmune diseases, enabling self-administration and potentially enhancing patient adherence to therapy. For example, in March 2024, Celltrion, a biopharmaceutical company based in South Korea, introduced Zymfentra, a biosimilar to Remicade (infliximab), priced at $6,181.08 for two doses over four weeks. This formulation received FDA approval as the first subcutaneous infliximab option for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn's disease. Eligible patients with commercial insurance can access copay assistance of $5 per month, while uninsured or underinsured individuals may receive Zymfentra at no cost.

In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsung Bioepis Co. Ltd. for $2.3 billion. This acquisition positions Samsung Biologics to meet the increasing demand for biosimilars, access a broader range of products, expand manufacturing capacity, and strengthen its global reach. Samsung Bioepis Co. Ltd. is a South Korea-based biopharmaceutical company specializing in producing Remicade biosimilar products.

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the remicade biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The remicade biosimilar market consists of sales of inflectra, renflexis, avolsa, remsima, infimab, and avolsa. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Remicade Biosimilar Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on remicade biosimilar market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remicade biosimilar ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The remicade biosimilar market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 100mg/10ml; 500mg/50ml
• 2) By Disease Indication: Ulcerative Colitis; Rheumatoid Arthritis; Ankylosing Spondylitis; Crohn's Disease; Psoriatic Arthritis; Plaque Psoriasis
• 3) By Application: Blood Disorders; Oncology Diseases
• Subsegments:
• 1) By 100 Mg/10 Ml: Vials For Injection; Prefilled Syringes
• 2) By 500 Mg/50 Ml: Vials For Injection; Prefilled Syringes
• Companies Mentioned: Novartis AG; Amgen Inc; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Biogen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Remicade Biosimilar Market Characteristics

3. Remicade Biosimilar Market Trends And Strategies

4. Remicade Biosimilar Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Remicade Biosimilar Growth Analysis And Strategic Analysis Framework

• 5.1. Global Remicade Biosimilar PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Remicade Biosimilar Market Growth Rate Analysis
• 5.4. Global Remicade Biosimilar Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Remicade Biosimilar Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Remicade Biosimilar Total Addressable Market (TAM)

6. Remicade Biosimilar Market Segmentation

• 6.1. Global Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100mg/10ml
• 500mg/50ml
• 6.2. Global Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ulcerative Colitis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Crohn's Disease
• Psoriatic Arthritis
• Plaque Psoriasis
• 6.3. Global Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Disorders
• Oncology Diseases
• 6.4. Global Remicade Biosimilar Market, Sub-Segmentation Of 100 Mg/10 Ml, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vials For Injection
• Prefilled Syringes
• 6.5. Global Remicade Biosimilar Market, Sub-Segmentation Of 500 Mg/50 Ml, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vials For Injection
• Prefilled Syringes

7. Remicade Biosimilar Market Regional And Country Analysis

• 7.1. Global Remicade Biosimilar Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Remicade Biosimilar Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Remicade Biosimilar Market

• 8.1. Asia-Pacific Remicade Biosimilar Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Remicade Biosimilar Market

• 9.1. China Remicade Biosimilar Market Overview
• 9.2. China Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Remicade Biosimilar Market

• 10.1. India Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Remicade Biosimilar Market

• 11.1. Japan Remicade Biosimilar Market Overview
• 11.2. Japan Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Remicade Biosimilar Market

• 12.1. Australia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Remicade Biosimilar Market

• 13.1. Indonesia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Remicade Biosimilar Market

• 14.1. South Korea Remicade Biosimilar Market Overview
• 14.2. South Korea Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Remicade Biosimilar Market

• 15.1. Western Europe Remicade Biosimilar Market Overview
• 15.2. Western Europe Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Remicade Biosimilar Market

• 16.1. UK Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Remicade Biosimilar Market

• 17.1. Germany Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Remicade Biosimilar Market

• 18.1. France Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Remicade Biosimilar Market

• 19.1. Italy Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Remicade Biosimilar Market

• 20.1. Spain Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Remicade Biosimilar Market

• 21.1. Eastern Europe Remicade Biosimilar Market Overview
• 21.2. Eastern Europe Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Remicade Biosimilar Market

• 22.1. Russia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Remicade Biosimilar Market

• 23.1. North America Remicade Biosimilar Market Overview
• 23.2. North America Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Remicade Biosimilar Market

• 24.1. USA Remicade Biosimilar Market Overview
• 24.2. USA Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Remicade Biosimilar Market

• 25.1. Canada Remicade Biosimilar Market Overview
• 25.2. Canada Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Remicade Biosimilar Market

• 26.1. South America Remicade Biosimilar Market Overview
• 26.2. South America Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Remicade Biosimilar Market

• 27.1. Brazil Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Remicade Biosimilar Market

• 28.1. Middle East Remicade Biosimilar Market Overview
• 28.2. Middle East Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Remicade Biosimilar Market

• 29.1. Africa Remicade Biosimilar Market Overview
• 29.2. Africa Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Remicade Biosimilar Market Competitive Landscape And Company Profiles

• 30.1. Remicade Biosimilar Market Competitive Landscape
• 30.2. Remicade Biosimilar Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Remicade Biosimilar Market Other Major And Innovative Companies

• 31.1. Merck And Co. Inc.
• 31.2. LG Chem Ltd.
• 31.3. Nippon Kayaku Co. Ltd.
• 31.4. Celltrion Inc.
• 31.5. Nichi-iko Pharmaceutical Co. Ltd.
• 31.6. Biocon Limited
• 31.7. Alvotech S.A.
• 31.8. MabPharm Ltd.
• 31.9. Genor Biopharma Co. Ltd
• 31.10. Shanghai Biomabs Pharmaceuticals Co. Ltd.
• 31.11. Samsung Bioepis Co. Ltd.
• 31.12. Biocad Biopharmaceutical Co
• 31.13. EPIRUS Biopharmaceuticals Inc.
• 31.14. Ranbaxy Laboratories Limited
• 31.15. BioXpress Therapeutics SA

32. Global Remicade Biosimilar Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Remicade Biosimilar Market

34. Recent Developments In The Remicade Biosimilar Market

35. Remicade Biosimilar Market High Potential Countries, Segments and Strategies

• 35.1 Remicade Biosimilar Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Remicade Biosimilar Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Remicade Biosimilar Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer